Leukemia
Conditions
Keywords
leukemia, Swedish Massage, Peppermint Inhalation, Nausea, Vomiting, Chemotherapy, Children
Brief summary
Clinical trials was used to compare the effect of peppermint inhalation and Swedish massage on chemotherapy induced-nausea and vomiting in children with leukemia. the main research hypotheses are: * Children with leukemia who receive peppermint inhalation exhibit less chemotherapy induced- nausea and vomiting than those who don't receive. * Children with leukemia who receive Swedish massage exhibit less chemotherapy induced-nausea and vomiting than those who don't receive. * Children with leukemia who receive Swedish massage exhibit less chemotherapy induced- nausea and vomiting than those who receive peppermint inhalation. children divided into three groups of study ( control group, peppermint inhalation group and Swedish massage group) to identify its effect on chemotherapy induced nausea and vomiting.
Interventions
BEHAVIORALPeppermint Inhalation
The researcher applied two drops (0,2ml) of 2% essential oil of peppermint on a piece of cotton. Then, each child was instructed to take three breaths of the essence that had been put on a piece of cotton before starting chemotherapy session with three minutes. In addition, the piece of cotton with peppermint essence was kept at bed side table to use by child as needed throughout the chemotherapy session. Inhalation of peppermint essence was applied for three consecutive chemotherapy sessions.
BEHAVIORALSwedish Massage
Children were received Swedish massage therapy for twenty minutes prior to chemotherapy session in a private and special room with effleurage, petrissage, friction, and tapotement and vibration movements for three consecutive chemotherapy sessions. The researcher applied facilitating olive oil in hands and pre warmed before applying massage. The massage technique was applied in prone position with mild to moderate pressure with guidance by the child's feedback and tolerance by using non-scented olive oil. Children's privacy was considered.
Sponsors
Alexandria University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
6 Years to 15 Years
Healthy volunteers
No
Inclusion criteria
* Received first chemotherapy session * Intact skin in the massage
Exclusion criteria
* Chronic and acute disorders such as respiratory, cardiovascular diseases...etc. * Allergy from any essential oils.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of delayed vomiting. | On second and third days after first chemotherapy administration.On second and third days after second chemotherapy administration. On second and third days after third chemotherapy administration. | once/ twice/ three times and more. |
| Worst of acute vomiting. | First 24 hours after first chemotherapy administration of study. Assessed within the first 24 hours after second chemotherapy administration of study. Assessed within the first 24 hours after third chemotherapy administration of study. | No/Mild/Moderate/severe/intolerable |
| Experience of delayed vomiting. | On second and third days after first chemotherapy administration.On second and third days after second chemotherapy administration. On second and third days after third chemotherapy administration. | Yes/ No. |
| Amount of acute vomiting. | First 24 hours after first chemotherapy administration of study. Assessed within the first 24 hours after second chemotherapy administration of study. Assessed within the first 24 hours after third chemotherapy administration of study. | Small/ Moderate/ large |
| Frequency of acute vomiting. | First 24 hours after first chemotherapy administration of study. Assessed within the first 24 hours after second chemotherapy administration of study. Assessed within the first 24 hours after third chemotherapy administration of study. | once/ twice/ three times and more. |
| Experience of delayed nausea. | On second and third days after first chemotherapy administration.On second and third days after second chemotherapy administration. On second and third days after third chemotherapy administration. | Yes/ No. |
| Worst of delayed nausea. | On second and third days after first chemotherapy administration.On second and third days after second chemotherapy administration. On second and third days after third chemotherapy administration. | No/Mild/Moderate/severe/intolerable |
| Worst of delayed vomiting. | On second and third days after first chemotherapy administration.On second and third days after second chemotherapy administration. On second and third days after third chemotherapy administration. | No/Mild/Moderate/severe/intolerable |
| Amount of delayed vomiting. | On second and third days after first chemotherapy administration.On second and third days after second chemotherapy administration. On second and third days after third chemotherapy administration. | Small/ Moderate/ large |
| Duration of delayed nausea. | On second and third days after first chemotherapy administration.On second and third days after second chemotherapy administration. On second and third days after third chemotherapy administration. | /hours. |
| Experience of anticipatory nausea | assessed immediately before chemotherapy administration for three consecutive chemotherapy sessions | Yes/No |
| Worst of anticipatory nausea | assessed immediately before chemotherapy administration for three consecutive chemotherapy sessions | No/Mild/Moderate/severe/intolerable |
| Duration of anticipatory nausea | assessed immediately before chemotherapy administration for three consecutive chemotherapy sessions | /Minutes |
| Frequency of anticipatory nausea | assessed immediately before chemotherapy administration for three consecutive chemotherapy sessions | once/twice/ three times and more |
| Frequency of delayed nausea. | On second and third days after first chemotherapy administration.On second and third days after second chemotherapy administration. On second and third days after third chemotherapy administration. | once/ twice/ three times and more. |
| Experience of anticipatory vomiting | assessed immediately before chemotherapy administration for three consecutive chemotherapy sessions | Yes/No |
| Worst of anticipatory vomiting | assessed immediately before chemotherapy administration for three consecutive chemotherapy sessions | No/Mild/Moderate/severe/intolerable |
| Amount of anticipatory vomiting | assessed immediately before chemotherapy administration for three consecutive chemotherapy sessions | Small/ Moderate/ Large |
| Frequency of anticipatory vomiting | assessed immediately before chemotherapy administration for three consecutive chemotherapy sessions | once/ twice/ three times and more. |
| Experience of acute nausea . | First 24 hours after first chemotherapy administration of study. Assessed within the first 24 hours after second chemotherapy administration of study. Assessed within the first 24 hours after third chemotherapy administration of study. | Yes/no. |
| Worst of acute nausea . | First 24 hours after first chemotherapy administration of study. Assessed within the first 24 hours after second chemotherapy administration of study. Assessed within the first 24 hours after third chemotherapy administration of study. | No/Mild/Moderate/severe/intolerable |
| Duration of acute nausea . | Frst 24 hours after first chemotherapy administration of study. Assessed within the first 24 hours after second chemotherapy administration of study. Assessed within the first 24 hours after third chemotherapy administration of study. | /hours. |
| Frequency of acute nausea . | First 24 hours after first chemotherapy administration of study. Assessed within the first 24 hours after second chemotherapy administration of study. Assessed within the first 24 hours after third chemotherapy administration of study. | once/ twice/ three times and more. |
| Experience of acute vomiting. | First 24 hours after first chemotherapy administration of study. Assessed within the first 24 hours after second chemotherapy administration of study. Assessed within the first 24 hours after third chemotherapy administration of study. | Yes/No. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Onset of the disease | Before data collection | months |
| Type of leukemia | Before data collection | Acute Lymphoblastic Leukemia / Acute Myeloid Leukemia/ Chronic Lymphocytic Leukemia / Chronic Myeloid Leukemia |
| Prescribed chemotherapy medications | Before data collection | Methotrexate / cytarabine |
| Antiemetics prescribed medications | Before data collection | Ondansetron |
| Child's age | Before data collection | years |
| Gender | Before data collection | male/female |
| Residence | Before data collection | rural/urban |
| Level of education | Before data collection | kinder garden/primary |
Countries
Egypt
Outcome results
None listed